Exit Dr Reddy's Laboratories: Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "One should book the losses in Dr Reddy's Laboratories while I do think that over a three to five year period thing should improve and we could relook at the stock. But I think over the next one year the issues regarding the product launches in US is going to be continued to be affected by these US FDA issues that they are having."

"I was in fact hoping that it could have got sorted out now but now it looks like it is another year. If you saw the last couple of quarters last quarter also you see the run rate for the US market has almost now come down. It is now almost 75 million revenue versus 100 that we used to see earlier. So there is actually seen a drop and there is no sight of improvement."

"Even Gleevec as you know their launch partner has got a 484 notice on it, so there is a delay in launches plus they have lost some of the cases that I was hoping that they would win for the anti nausea in the recent past. So, there are lot of negatives coming together, valuations are expensive. So, there will be a consolidation in this sort of range for at least another six months. So it is better to book your losses and then re-look at it after some time when the issues are sorted out," she added.